Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis.

BACKGROUND Recent studies have suggested a possible association between pneumonia and the use of inhaled corticosteroids. We aimed to ascertain the risk of pneumonia with long-term inhaled corticosteroid use among patients with chronic obstructive pulmonary disease (COPD). METHODS We performed systematic searches with no date restrictions through June 30, 2008, of MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, regulatory documents, and trial registries. We included randomized controlled trials of any inhaled corticosteroid vs a control treatment for COPD, with at least 24 weeks of follow-up and reporting of pneumonia as an adverse event. Outcomes evaluated included any pneumonia, serious pneumonia, pneumonia-related mortality, and overall mortality. RESULTS Eighteen randomized controlled trials (n = 16 996) with 24 to 156 weeks of follow-up were included after a detailed screening of 97 articles. Inhaled corticosteroids were associated with a significantly increased risk of any pneumonia (relative risk [RR], 1.60; 95% confidence interval [CI], 1.33-1.92 [P < .001]; I(2) = 16%) and serious pneumonia (1.71; 1.46-1.99 [P < .001]; I(2) = 0%) but without a significantly increased risk of pneumonia-related mortality (1.27; 0.80-2.03 [P = .31]; I(2) = 0%) or overall mortality (0.96; 0.86-1.08 [P = .51]; I(2) = 0%). Inhaled corticosteroids were associated with a significantly increased risk of serious pneumonia when compared with placebo (RR, 1.81; 95% CI, 1.44-2.29 [P < .001]) or when the combination of inhaled corticosteroids and long-acting beta-agonists was compared with long-acting beta-agonists (1.68; 1.20-2.34 [P = .002]). CONCLUSION Among patients with COPD, inhaled corticosteroid use for at least 24 weeks is associated with a significantly increased risk of serious pneumonia, without a significantly increased risk of death.

[1]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[2]  A. Anzueto,et al.  Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.

[3]  S. Suissa,et al.  Methodological issues in therapeutic trials of COPD , 2008, European Respiratory Journal.

[4]  S. Suissa,et al.  METHODOLOGICAL ISSUES IN THERAPEUTIC TRIALS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE , 2008 .

[5]  A. Anzueto,et al.  Effect of fluticasone propionate/salmeterol (250/50 g) or salmeterol (50 g) on COPD exacerbations , 2008 .

[6]  J. Maurer.  Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial , 2008 .

[7]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[8]  T. Wilt,et al.  Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline , 2007, Annals of Internal Medicine.

[9]  A. Gonzalez,et al.  Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. , 2007, American journal of respiratory and critical care medicine.

[10]  J. Bourbeau,et al.  Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease , 2007, Annals of Internal Medicine.

[11]  D. Postma,et al.  A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. , 2007, Chest.

[12]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[13]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[14]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.

[15]  A. Anzueto,et al.  COPD is associated with increased mortality in patients with community-acquired pneumonia , 2006, European Respiratory Journal.

[16]  S. Suissa,et al.  Low-dose inhaled and nasal corticosteroid use and the risk of cataracts , 2006, European Respiratory Journal.

[17]  K. Lohr,et al.  Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes , 2006, The Annals of Family Medicine.

[18]  Frederick Wolfe,et al.  Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. , 2006, Arthritis and rheumatism.

[19]  P. Barnes.  Reduced histone deacetylase in COPD: clinical implications. , 2006, Chest.

[20]  D. Postma,et al.  Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial , 2005, Thorax.

[21]  I. Adcock,et al.  Decreased histone deacetylase activity in chronic obstructive pulmonary disease. , 2005, The New England journal of medicine.

[22]  M. Rosenberg,et al.  THE FILE‐DRAWER PROBLEM REVISITED: A GENERAL WEIGHTED METHOD FOR CALCULATING FAIL‐SAFE NUMBERS IN META‐ANALYSIS , 2005, Evolution; international journal of organic evolution.

[23]  D. Postma,et al.  Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease , 2005, Thorax.

[24]  S. Suissa,et al.  Inhaled and nasal corticosteroid use and the risk of fracture. , 2004, American journal of respiratory and critical care medicine.

[25]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[26]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[27]  N. Hanania,et al.  The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD , 2003 .

[28]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[29]  A. Gillissen,et al.  Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study , 2003, Thorax.

[30]  C. Strange,et al.  Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. , 2003, Annals of internal medicine.

[31]  J. van der Palen,et al.  Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.

[32]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[33]  C L Bartlett,et al.  Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. , 2000, Respiratory medicine.

[34]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[35]  Barnes Pj.  Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. , 2000 .

[36]  P. Barnes.  Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[37]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[38]  I. Bolíbar,et al.  Risk factors for community-acquired pneumonia in adults: a population-based case-control study. , 1999, The European respiratory journal.

[39]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[40]  A. LaCroix,et al.  Prospective study of pneumonia hospitalizations and mortality of U.S. older people: the role of chronic conditions, health behaviors, and nutritional status. , 1989, Public health reports.